Abstract
A growing awareness about brain health and Alzheimer's disease in the general population is leading to an increasing number of cognitively unimpaired individuals, who are concerned that they have reduced cognitive function, to approach the medical system for help. The term subjective cognitive decline (SCD) was conceived in 2014 to describe this condition. Epidemiological data provide evidence that the risk for mild cognitive impairment and dementia is increased in individuals with SCD. However, the majority of individuals with SCD will not show progressive cognitive decline. An individually tailored diagnostic process might be reasonable to identify or exclude underlying medical conditions in an individual with SCD who actively seeks medical help. An increasing number of studies are investigating the link between SCD and the very early stages of Alzheimer's disease and other neurodegenerative diseases.
| Original language | English |
|---|---|
| Pages (from-to) | 271-278 |
| Number of pages | 8 |
| Journal | The Lancet. Neurology |
| Volume | 19 |
| Issue number | 3 |
| Early online date | 17 Jan 2020 |
| DOIs | |
| Publication status | Published - Mar 2020 |
Funding
We declare no financial relationships directly related to this work. The following grants focus on the topic and results of this article, or support the author's related research: DZNE-DELCODE, BN012 (FJ); Medit-Ageing EU H2020, call PHC22 (FJ, JLM); AMYPAD EU-EFPIA IMI 2, grant 115952 (FJ, JLM); MOPEAD EU-EFPIA IMI 2, grant 115985 (FJ, ORG); EU JPND, Germany (BMBF grant 01ED1508 [FJ], the Netherlands [WMvdF]); SCIENCe project, Gieskes Strijbis Fonds (WMvdF); WMvdF holds the Pasman chair; Zon-MW Off Road, grant 451 001 010 (SAMS); Key Project, grant 61633018 (NSFC; YH); IH/NIA 1R01AG058825?01A1 (REA); National Institute on Aging, grants R01 AG019771, P30 AG010133, and U01 AG024904 (AJS). The following financial relationships outside of the presented work include the following: personal fees for advice from Eli Lilly, Biogen, MSD, Roche, Nutricia, and Janssen-Cilag, and grant support from Eli Lilly (FJ); grant support from Gieskes-Strijbis fonds, ZonMW, CVON, Pasman stichting, Biogen MA, Combinostics, NWO, EU-FP7, Piramal Neuroimaging, and Janssen-Stellar (WMvdF); personal fees for advice from Roche Diagnostics, Eisai, Oryzon, Roche, Biogen, and Novartis, and grant support from General Electric (JLM); fees for advice from Neurotrack and Eli Lilly (DMR); grant support from NIA (AJS); grant support from ZonMW Off Road (SAMS); fees for advice from Neurotrack and Eli Lilly (CMS); and REA, RFB, YH, LR, ORG, SW, and MW report no disclosures.
| Funders | Funder number |
|---|---|
| Piramal Neuroimaging | |
| Nederlandse Organisatie voor Wetenschappelijk Onderzoek | |
| Biogen | |
| EU JPND | |
| Cilag | |
| Eli Lilly and Company | |
| Division of Materials Research | |
| EU-FP7 | |
| Gieskes-Strijbis Fonds | |
| ZonMW Off Road | |
| Novartis | |
| CVON | |
| Roche | |
| ZonMw | |
| General Electric | |
| JLM | |
| Meso Scale Diagnostics | |
| National Institute on Aging | U01AG024904, P30AG010133, R01AG058825, K23AG044431, R01AG019771 |
| Horizon 2020 Framework Programme | 667696, MOPEAD EU-EFPIA IMI 2, 115985, 115952, AMYPAD EU-EFPIA IMI 2 |
| Bundesministerium für Bildung und Forschung | 01ED1508 |
| National Natural Science Foundation of China | 01A1 |
| Shandong Academy of Medical Sciences | 61633018 |
| Gieskes Strijbis Fonds | 451 001 010 |
